|

XNW5004 Clinical Trials

1 actively recruiting trial

▼ -1 trial since July 2026

Also known as: EZH2i

Pipeline

Phase 1/2: 1

Top Sponsors

  • Evopoint Biosciences Inc.1

Indications

  • mCRPC (Metastatic Castration-resistant Prostate Cancer)1
  • Metastatic Castrate-Resistant Prostate Cancer1
  • Cancer1

Other1 trial

Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.